Company intelligence / Profile preview

Emergent BioSolutions

Gaithersburg, Maryland, United Statesemergentbiosolutions.com ↗

Ownership: Public · EBS
Employees: ~5000
Development stage: Commercial

Overview

Emergent BioSolutions has multiple commercial products including BioThrax (Anthrax Vaccine Absorbed), CYFENDUS (Anthrax Vaccine Absorbed, Adjuvanted), ACAM2000 (Smallpox and Mpox Vaccine), NARCAN Nasal Spray (naloxone HCl), and KLOXXADO (naloxone HCI) Nasal Spray 8 mg. The company has over 100 clinical trials and approximately 20 marketed drugs.

Therapeutic areas: NeurologyInfectious Diseases
Modalities: VaccinesTherapeuticsDrug-device combination products
Industry: Biotech

Drug pipeline

39 assets

anthrax immune globulin human

Approved

38 more assets in the full pipeline.

Request access →

Partnerships

U.S. government (BARDA, NIAID)Ridgeback Therapeutics

Financials

Market cap: $309.6M
Total revenue: $234.3M
Enterprise value: $751.7M

Beyond the preview

Go deeper on Emergent BioSolutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Emergent BioSolutions.

Explore the full profile